Insider Trading Review: Medtronic PLC $MDT

c9b9ae1b4267024d489995d8371bbb3b

Medtronic PLC (NYSE:MDT) insider have most recently took part in a trading activity. On Jun 21, 2017 Anderson Richard H, Director bought 5,600 shares having total worth of $497,840 at the price of $88.9 per share, following the transaction a total of 79,215 shares owned by Anderson Richard H.

Furthermore, over the past 12 months , the stock was traded 15 times by insiders. In 13 of these trades, the insider was a seller while an employee of the company was the buyer in 2 instances.

Shares of Medtronic PLC (NYSE:MDT) traded down 0.03% on Jun 21, 2017, hitting $88.79. 3,549,356 shares of the company’s stock traded hands. Medtronic PLC has a 52 week low of $70.61 and a 52 week high of $88.99. The company’s market cap is $119,770 million.

Medtronic PLC (NYSE:MDT) last announced its earnings results on May 25, 2017. The company reported 1.33 earnings per share (EPS) for the quarter, higher than the consensus estimate of 1.31 by $0.02. The company had revenue of $7,916 million for the quarter, compared to the consensus estimate of $7,860 million. During the same quarter in the previous year, the company posted 1.27 earnings per share. The company’s revenue for the quarter was up 5% on a year-over-year basis.

2017-05-25 2017-02-21 2016-11-22 2016-08-25 2016-05-31 2016-03-01 2015-12-03 2015-09-03 2015-06-02 2015-02-17
earnings per share 1.33 1.12 1.12 1.03 1.27 1.06 1.03 1.02 1.16 1.01
Revenue(M) 7916 7283 7345 7166 7567 6934 7058 7274 7304 4318

Medtronic, Inc., was incorporated as a Minnesota corporation in 1957. The Company is engaged in providing medical technology- alleviating pain, restoring health, and extending life for people. The Company develops, manufactures, and markets its medical devices in more than 140 countries. Its products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose, and throat conditions. The Company’s operating segments are: Cardiac and Vascular Group; and Restorative Therapies Group. Cardiac and Vascular Group includes Cardiac Rhythm Disease Management (CRDM) and CardioVascular. Restorative Therapies Group includes Spinal, Neuromodulation, Diabetes, and Surgical Technologies. CRDM develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), and information systems for the management of patients with CRDM devices. CardioVascular is composed of the following three businesses: Coronary, Endovascular and Peripheral, and Structural Heart. Its Spinal business develops, manufactures, and markets a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its Neuromodulation business develops, manufactures, and markets medical devices for the treatment of chronic pain, movement disorders, psychological disorders, and urological, fecal, and gastroenterological disorders. Its Diabetes business develops, manufactures, and markets advanced, integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring systems, and therapy management software. Its Surgical Technologies business develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose, and throat (ENT) and certain neurological disorders. In addition, the business develops, manufactures, and markets image-guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus, and orthopedic surgeries. Its main customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. Its competitors are St. Jude Medical, Inc., Boston Scientific Corporation, Biotronik, Inc., Sorin Group, Abbott Laboratories and Boston Scientific, GETINGE AB, and Terumo Medical Corporation. The Company’s medical devices are subject to regulation by numerous government agencies, including the U.S.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.